
浏览全部资源
扫码关注微信
1.563099 贵州 遵义,遵义医科大学第二附属医院检验科
2.400037 重庆,陆军军医大学(第三军医大学)第二附属医院血液病医学中心,全军血液病中心,创伤、烧伤与复合伤国家重点实验室
[葛晓军,E-mail: gxj_199421@163.com GE Xiaojun, E-mail: gxj_199421@163.com
[杨世杰,E-mail: xyzysj102@163.com YANG Shijie, E-mail: xyzysj102@163.com
收稿:2021-08-10,
修回:2021-09-20,
纸质出版:2021-11-15
移动端阅览
杜雨軒, 王平, 葛晓军, 等. 慢性移植物抗宿主病患者免疫细胞亚群分选的表面标志组合策略[J]. 第三军医大学学报, 2021,43(21):2331-2336.
Yuxuan DU, Ping WANG, Xiaojun GE, et al. A combined strategy of surface markers for sorting immune cell subsets in patients with chronic graft-versus-host disease[J]. Journal of Third Military Medical University, 2021, 43(21): 2331-2336.
杜雨軒, 王平, 葛晓军, 等. 慢性移植物抗宿主病患者免疫细胞亚群分选的表面标志组合策略[J]. 第三军医大学学报, 2021,43(21):2331-2336. DOI: 10.16016/j.1000-5404.202108057.
Yuxuan DU, Ping WANG, Xiaojun GE, et al. A combined strategy of surface markers for sorting immune cell subsets in patients with chronic graft-versus-host disease[J]. Journal of Third Military Medical University, 2021, 43(21): 2331-2336. DOI: 10.16016/j.1000-5404.202108057.
目的
2
观测慢性移植物抗宿主病(chronic graft-versus-host disease
cGVHD)患者免疫细胞亚群分布变化规律,探讨免疫细胞表面标志物分选出的特定细胞亚群在cGVHD发病过程中对疾病发展的预测作用。
方法
2
收集2020年10月至2021年7月在陆军军医大学第二附属医院血液病医学中心接受造血干细胞移植后的患者58例,根据移植后是否发生cGVHD分为cGVHD组(发生cGVHD,
n
=43)和对照组(未发生cGVHD,
n
=15),采用流式细胞术分析两组患者免疫细胞亚群比率及分布情况,募集患者原发诊断包括ALL、AML、CML、MDS、SAA和重型β地中海贫血。其中发生cGVHD的中位时间为178.5(47~1 328)d,每例患者于随访过程中发生cGVHD时或病程中随访当日留取外周血标本。
结果
2
cGVHD组患者外周血中调节性T细胞(regulatory T cells,Tregs)及过渡型B细胞的分布水平显著降低,CD19
+
B淋巴细胞的分布水平较对照组显著增加;接受造血干细胞移植后发生cGVHD的患者组外周血中Tregs较接受造血干细胞移植后未发生cGVHD的患者组明显降低,中度cGVHD患者Th17细胞较轻度患者分布水平显著升高,CD19
+
B淋巴细胞在轻度、中度患者中显著升高;比较不同cGVHD靶器官,仅累及皮肤病变的患者与仅累及肝脏的患者Tregs较对照组中显著降低,而合并皮肤及肝脏损伤患者的外周血中滤泡辅助T细胞的分布显著高于仅累及黏膜或眼睛等器官的患者。
结论
2
移植后免疫细胞亚群检测是临床辅助cGVHD诊疗随访的重要参考指标。使用免疫细胞表面标志组合的特异性策略分选出的调节性T细胞、过渡型B细胞对cGVHD患者的发病及严重程度、靶器官损伤都有特异性的指示作用。
Objective
2
To explore the distribution of immune cell subsets in patients with chronic graft-versus-host disease (cGVHD) and investigate the predictive values of specific cell subsets sorted by surface markers in the development of cGVHD.
Methods
2
From October 2020 to July 2021
58 patients who received he
matopoietic stem cell transplantation (HSCT) from the Hematology Medical Center of the Second Affiliated Hospital of the Army Medical University were collected in this study. Flow cytometry was used to detect the ratio of immune cell subpopulations in the cGVHD patients (cGVHD group
n
=43) and those without (control group
n
=15) who received allogeneic HSCT during the same period. Primary diagnoses of the recruited patients included acute lymphoblastic leukemia (ALL)
acute myeloid leukemia (AML)
chronic myeloid leukemia (CML)
myelodysplastic syndromes (MDS)
severe aplastic anemia (SAA)
and β-thalassemia major. The median time to occurrence of cGVHD was 178.5 (47~1 328) d. Peripheral blood (PB) samples were collected for each patient when cGVHD occurred during follow-up or on the day of follow-up during the course of the disease.
Results
2
The percentages of PB regulatory T cells (Tregs) and transitional B cells were significantly reduced in the cGVHD group (
P
<
0.05)
and that of CD19
+
B lymphocytes was higher than the control group. The percentage of Tregs differed from the cGVHD patients with different severities (
P
<
0.05). The percentage of Th17-like cells in the patients with moderate cGVHD was significantly higher than patients with mild cGVHD. CD19
+
B lymphocytes showed higher percentage in the patients with mild and moderate cGVHD. In the comparison among different targeted organs of cGVHD
only the Tregs percentage was significantly lower in the patients with skin and liver damage than control group
while the percentage of follicular helper T cells in the patients with skin and liver damage was significantly higher than those only having mucous membrane or eye organ involvement.
Conclusion
2
Distribution of immune cell subsets after HSCT is an important reference marker for the diagnosis
treatment and prognosis of cGVHD. Treg cells and transitional B cells which are sorted with a special combined strategy of surface markers play specific guiding roles in the pathogenesis
severity and damage of targeted organs of cGVHD.
ZHAO L, CHEN S Q, YANG P X, et al . The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease[J ] . Stem Cell Res Ther, 2019, 10(1): 182. DOI: 10.1186/s13287-019-1287-9.
陈婷, 李小平, 张诚, 等. 慢性移植物抗宿主病患者血清特异性生物标志物的临床研究[J]. 中华血液学杂志, 2019, 40(11): 948-952. DOI: 10.3760/cma.j.issn.0253-2727.2019.11.012.
CHEN T, LI X P, ZHANG C, et al . The clinical observation of serum specific biomarkers in patients with chronic graft-versus-host disease[J ] . Chin J Hematol, 2019, 40(11): 948-952. DOI: 10.3760/cma.j.issn.0253-2727.2019.11.012.
JAGASIA M H, GREINIX H T, ARORA M, et al . National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-Host Disease: I the 2014 diagnosis and staging working group report[J ] . Biol Blood Marrow Transplant, 2015, 21(3): 389-401. e1. DOI: 10.1016/j.bbmt.2014.12.001.
MACDONALD K P, HILL G R, BLAZAR B R. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies[J]. Blood, 2017, 129(1): 13-21. DOI: 10.1182/blood-2016-06-686618.
DEKKER L, DE KONING C, LINDEMANS C, et al . Reconstitution of T cell subsets following allogeneic hematopoietic cell transplantation[J ] . Cancers, 2020, 12(7): 1974. DOI: 10.3390/cancers12071974.
LIN A E, REYES S, AN X Y, et al . Experimental modeling of acute- and chronic-GVHD by xenotransplanting human donor PBMCs or cord blood CD34 + cells (HSC) into NSG mice[J ] . Blood, 2018, 132(Supplement 1): 5684. DOI: 10.1182/blood-2018-99-115462..
SOARES M V D, AZEVEDO R I, FERREIRA I A, et al . TREG and tcon dynamics after allo-HSCT: cGVHD is associated to decreased NaïVe and stem cell memory subsets with a concomitant increase in terminally differentiated T cell subsets[J ] . Blood, 2016, 128(22): 2229. DOI: 10.1182/blood.v128.22.2229.2229.
KINSELLA S, DUDAKOV J A. When the damage is done: injury and repair in thymus function[J]. Front Immunol, 2020, 11: 1745. DOI: 10.3389/fimmu.2020.01745.
LI X P, GAO Q G, FENG Y M , et al . Developing role of B cells in the pathogenesis and treatment of chronic GVHD[J ] . Br J Haematol, 2019, 184(3): 323-336. DOI: 10.1111/bjh.15719.
SARVARIA A, BASAR R, MEHTA R S, et al . IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation[J ] . Blood, 2016, 128(10): 1346-1361. DOI: 10.1182/blood-2016-01-695122.
CHEN X, LAI P, WANG Y, et al . Emerging role of C5a/C5aR IL-17A axis in cGVHD[J ] . Am J Transl Res, 2018, 10(7): 2148-2157.
FORCADE E, PAZ K, FLYNN R, et al . An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition[J ] . JCI Insight, 2017, 2(12): e92111. DOI: 10.1172/jci.insight.92111.
MARAVILLAS-MONTERO J L, ACEVEDO-OCHOA E. Human B regulatory cells: the new players in autoimmune disease[J]. Rev Invest Clin, 2017, 69(5): 243-246. DOI: 10.24875/ric.17002266.
VERGHESE D A, CHUN N, PAZ K, et al . C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obli terans[J ] . JCI Insight, 2018, 3(24): e124646. DOI: 10.1172/jci.insight.124646.
BEURIER P, RICARD L, ESHAGH D, et al . TFH cells in systemic sclerosis[J ] . J Transl Med, 2021, 19(1): 375. DOI: 10.1186/s12967-021-03049-0.
SAIDU N E B, BONINI C, DICKINSON A, et al . New approaches for the treatment of chronic graft-versus-host disease: current status and future directions[J ] . Front Immunol, 2020, 11: 578314. DOI:10.3389/fimmu.2020.578314.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621